Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | BTN3A1 | O00481 | 5/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18239653 | 0.84 | BTN3A1 (0.30) | BTN3A1 | |
| SCHEMBL7620877 | 0.83 | ALDH1A1 (0.43) | ALDH1A1LMNAHSD17B10BTN3A1GLA | |
| SCHEMBL18239629 | 0.82 | NAAA (0.34) | ALDH1A1 | |
| SCHEMBL18235486 | 0.82 | GLA (0.33) | ALDH1A1LMNAHSD17B10BTN3A1GLA | |
| SCHEMBL25381000 | 0.82 | ALDH1A1 (0.32) | ALDH1A1BTN3A1 | |
| SCHEMBL18239579 | 0.81 | — | — | |
| SCHEMBL25381004 | 0.80 | BTN3A1 (0.30) | BTN3A1 | |
| SCHEMBL25248665 | 0.80 | ADRA2A (0.33) | BTN3A1 | |
| SCHEMBL18239582 | 0.79 | ALDH1A1 (0.46) | ALDH1A1LMNAHSD17B10 | |
| SCHEMBL25222432 | 0.78 | BTN3A1 (0.36) | BTN3A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160333024-A1 | OXABICYCLOHEPTANE PRODRUGS | LIXTE BIOTECHNOLOGY, INC. (US) | 2016-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160333024-A1 | OXABICYCLOHEPTANE PRODRUGS | UGT2B7, UGT1A6, UGT1A1 | ALDH1A1 259/4885LMNA 4613/4885HSD17B10 516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.